Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) is anticipated to issue its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect the company to announce earnings of ($0.5825) per share and revenue of $61.9250 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, July 30, 2026 at 8:00 AM ET.
Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($0.82) EPS for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.13). Vanda Pharmaceuticals had a negative net margin of 109.99% and a negative return on equity of 32.26%. The business had revenue of $51.72 million for the quarter, compared to the consensus estimate of $54.98 million. On average, analysts expect Vanda Pharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Vanda Pharmaceuticals Trading Down 2.4%
VNDA opened at $5.35 on Thursday. Vanda Pharmaceuticals has a fifty-two week low of $4.14 and a fifty-two week high of $9.94. The firm has a market capitalization of $321.70 million, a PE ratio of -1.32 and a beta of 0.60. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.16 and a quick ratio of 2.15. The company’s 50-day moving average is $6.05 and its 200 day moving average is $6.96.
Wall Street Analysts Forecast Growth
Check Out Our Latest Stock Analysis on VNDA
Hedge Funds Weigh In On Vanda Pharmaceuticals
Hedge funds and other institutional investors have recently modified their holdings of the business. Russell Investments Group Ltd. increased its position in shares of Vanda Pharmaceuticals by 456.6% during the third quarter. Russell Investments Group Ltd. now owns 6,495 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 5,328 shares during the last quarter. Quarry LP purchased a new position in Vanda Pharmaceuticals in the third quarter worth $53,000. Cerity Partners LLC bought a new position in Vanda Pharmaceuticals in the 2nd quarter valued at $69,000. Boothbay Fund Management LLC bought a new position in Vanda Pharmaceuticals in the 3rd quarter valued at $72,000. Finally, Engineers Gate Manager LP purchased a new stake in shares of Vanda Pharmaceuticals during the 2nd quarter valued at $75,000. Hedge funds and other institutional investors own 88.14% of the company’s stock.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.
Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.
Featured Articles
- Five stocks we like better than Vanda Pharmaceuticals
- Could Truth API Become Trump Media’s First Meaningful Revenue Driver?
- Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying
- Moog Is More Than a Missile Maker, and Wall Street Is Noticing
- A Boring Dividend Growth Strategy Becomes a Solid Defensive Play
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
